• Special session for patients’ advocacy group

  • Advances in disease biology

  • Immunotherapy

  • Treatment guidelines for the young patients

  • Outcome prediction

  • Choice of therapy for non-transplant eligible patients

  • Guidelines in specific clinical situations

  • Treatment of relapse

  • Options for refractory myeloma

  • Ongoing clinical trials and future trials

  • CAR T cells in myeloma

  • Smoldering myeloma and MGUS

  • Practical guidelines for the practicing physician

  • AL amyloidosis

  • Waldenstrom macroglobulinemia